Diet ( DrugBank: - )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
86肺動脈性肺高血圧症67
97潰瘍性大腸炎72
240フェニルケトン尿症35
299嚢胞性線維症47

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04908397
(ClinicalTrials.gov)
September 29, 202117/5/2021Carnitine Consumption and Augmentation in Pulmonary Arterial HypertensionCarnitine Consumption and Augmentation in Pulmonary Arterial HypertensionPulmonary Arterial Hypertension;Familial Primary Pulmonary Hypertension;Primary Pulmonary Hypertension;Lung Diseases;Carnitine Nutritional DeficiencyDietary Supplement: L-carnitineVanderbilt University Medical CenterNULLRecruiting18 Years85 YearsAll12Phase 1United States
2NCT05318950
(ClinicalTrials.gov)
October 20, 201910/12/2021A nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIonA nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIon: Effect on quaLity of LifePulmonary Arterial HypertensionBehavioral: E-learning;Dietary Supplement: DietAmsterdam UMC, location VUmcReinier de Graaf Groep;Janssen-Cilag B.V.Completed18 Years80 YearsAll40N/ANetherlands
3EUCTR2012-000097-26-PL
(EUCTR)
27/02/201620/01/2016International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy. Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3Israel;Chile;Italy;United Kingdom;India;United States;Taiwan;Greece;Austria;France;Mexico;Canada;Argentina;Belgium;Poland;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of;Sweden
4EUCTR2012-000098-21-PL
(EUCTR)
27/02/201620/01/2016An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3Austria;Israel;Chile;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Belgium;Poland;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Sweden;Korea, Republic of;Greece;United States;Taiwan
5EUCTR2012-000098-21-FR
(EUCTR)
24/11/201526/09/2012An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 15.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
858Phase 3United States;Taiwan;Greece;Austria;Israel;Italy;United Kingdom;France;Mexico;Canada;Poland;Belgium;Brazil;Denmark;Australia;Germany;Netherlands;Sweden;Korea, Republic of
6EUCTR2012-000097-26-GR
(EUCTR)
05/08/201411/06/2014International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy Pulmonary Arterial Hypertension
MedDRA version: 17.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
858Phase 3France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Denmark;Peru;Australia;Netherlands;Germany;China;Korea, Republic of;Sweden;United States;Taiwan;Greece;Austria;Israel;Italy;United Kingdom;India
7EUCTR2012-000098-21-GR
(EUCTR)
05/08/201410/06/2014An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 17.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
858Phase 3United States;Taiwan;Greece;Austria;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Denmark;Peru;Australia;Netherlands;Germany;China;Sweden;Korea, Republic of
8EUCTR2012-000097-26-DK
(EUCTR)
31/07/201422/05/2014International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy. Pulmonary Arterial Hypertension
MedDRA version: 19.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Chile;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Denmark;Australia;Netherlands;Germany;China;Sweden;Korea, Republic of
9EUCTR2012-000098-21-DK
(EUCTR)
31/07/201422/05/2014An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Chile;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Denmark;Australia;Netherlands;Germany;China;Sweden;Korea, Republic of
10EUCTR2012-000097-26-BE
(EUCTR)
18/06/201414/04/2014International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy Pulmonary Arterial Hypertension
MedDRA version: 16.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostin
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
858Phase 3United States;Taiwan;Greece;Austria;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Denmark;Peru;Australia;Netherlands;Germany;China;Korea, Republic of;Sweden
11EUCTR2012-000098-21-BE
(EUCTR)
18/06/201414/04/2014An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 16.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
858Phase 3United States;Taiwan;Greece;Austria;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Denmark;Peru;Australia;Netherlands;Germany;China;Korea, Republic of;Sweden
12EUCTR2012-000097-26-SE
(EUCTR)
09/06/201410/04/2014International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy. Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot Recruiting Female: yes
Male: yes
850 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Taiwan;Greece;Austria;Israel;Chile;Italy;United Kingdom;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of;Sweden
13EUCTR2012-000098-21-SE
(EUCTR)
15/05/201410/04/2014An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Israel;Chile;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of;Sweden
14NCT02000856
(ClinicalTrials.gov)
November 201319/11/2013BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial HypertensionBEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDietary Supplement: Beetroot juiceUppsala UniversityKarolinska InstitutetCompleted18 YearsN/AAll15N/ASweden
15NCT01934582
(ClinicalTrials.gov)
August 201329/8/2013A Pharmacokinetic Substudy of the TDE-PH-304 ProtocolA Pharmacokinetic Substudy of Subjects Transitioning From Twice Daily to Three Times Daily Dosing of UT-15C SR (Treprostinil Diethanolamine) in the TDE-PH-304 ProtocolPulmonary Arterial HypertensionDrug: UT-15C SR;Drug: treprostinil diethanolamineUnited TherapeuticsNULLCompleted12 Years75 YearsAll13Phase 3United States
16EUCTR2012-000098-21-IT
(EUCTR)
22/05/201311/01/2013An Open Label Extension Study of UT-15C in subjects with PulmonaryArterial HypertensionAn Open Label Extension Study of UT-15C in subjects with PulmonaryArterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
Product Name: treprostinil diethanolamine
Product Code: UT-15C
Product Name: treprostinil diethanolamine
Product Code: UT-15C
Product Name: treprostinil diethanolamine
Product Code: UT-15C
Product Name: treprostinil diethanolamine
Product Code: UT-15C
UNITED THERAPEUTICSNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
858United States;Taiwan;Austria;Israel;Italy;United Kingdom;Mexico;Canada;Brazil;Australia;Germany;Netherlands;Korea, Republic of
17EUCTR2012-000097-26-IT
(EUCTR)
22/05/201319/12/2012International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy Pulmonary Arterial Hypertension
MedDRA version: 17.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostin
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
610Phase 3United States;Taiwan;Greece;Austria;Israel;Chile;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Sweden;Korea, Republic of
18EUCTR2012-000098-21-NL
(EUCTR)
05/03/201310/08/2012An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Chile;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Denmark;Australia;Germany;Netherlands;China;Sweden;Korea, Republic of
19EUCTR2012-000097-26-NL
(EUCTR)
18/02/201329/08/2012International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy. Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Israel;Chile;Italy;United Kingdom;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Germany;Netherlands;China;Korea, Republic of;Sweden
20EUCTR2012-000098-21-DE
(EUCTR)
14/11/201201/08/2012An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Chile;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Sweden;Korea, Republic of
21EUCTR2012-000097-26-GB
(EUCTR)
06/11/201201/08/2012International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy. Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot Recruiting Female: yes
Male: yes
850 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Taiwan;Greece;Austria;Israel;Chile;Italy;United Kingdom;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of;Sweden
22EUCTR2012-000098-21-GB
(EUCTR)
06/11/201201/08/2012An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostin
United Therapeutics CorporationNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
850 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Taiwan;Greece;Austria;Israel;Chile;Italy;United Kingdom;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of;Sweden
23EUCTR2012-000098-21-AT
(EUCTR)
18/10/201207/09/2012An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial HypertensionAn Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Chile;Israel;United Kingdom;Italy;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Sweden;Korea, Republic of
24EUCTR2012-000097-26-AT
(EUCTR)
21/09/201207/08/2012International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapyA Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension receiving background oral monotherapy Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
850Phase 3United States;Taiwan;Greece;Austria;Israel;Chile;Italy;United Kingdom;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of;Sweden
25EUCTR2012-000097-26-DE
(EUCTR)
17/09/201202/08/2012International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receivingbackground oral monotherapy A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy. Pulmonary Arterial Hypertension
MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot Recruiting Female: yes
Male: yes
850 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Taiwan;Greece;Austria;Israel;Chile;Italy;United Kingdom;India;France;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Australia;Denmark;Netherlands;Germany;China;Korea, Republic of;Sweden
26NCT01560637
(ClinicalTrials.gov)
May 20129/3/2012An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionOpen-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310Pulmonary Arterial HypertensionDrug: UT-15C (treprostinil diethanolamine)United TherapeuticsNULLCompleted18 Years75 YearsAll471Phase 3United States;Argentina;Australia;Austria;Brazil;Canada;Chile;China;Denmark;France;Germany;Greece;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Singapore;Sweden;Taiwan;United Kingdom
27NCT01446848
(ClinicalTrials.gov)
January 20123/10/2011Oral Iron Supplementation in Pulmonary HypertensionOral Iron Supplementation in Pulmonary HypertensionPulmonary Arterial HypertensionDietary Supplement: iron supplementThe Cleveland ClinicNULLCompleted21 YearsN/ABoth6N/AUnited States
28NCT01172496
(ClinicalTrials.gov)
August 201028/7/2010A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy VolunteersA Comparative Bioavailability Study of UT-15C SR (Treprostinil Diethanolamine, Sustained Release) Oral Tablets and UT-15C (Treprostinil Diethanolamine) Administered as an Oral Solution in Healthy VolunteersPulmonary Arterial HypertensionDrug: treprostinil diethanolamineUnited TherapeuticsNULLCompleted18 Years55 YearsBoth24Phase 1United States
29EUCTR2006-000804-18-PT
(EUCTR)
02/07/201025/01/2010An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
900Phase 3France;Portugal;Spain;Belgium;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
30NCT01153386
(ClinicalTrials.gov)
July 201028/6/2010Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil DiethanolamineAn Evaluation of the Pharmacokinetic Linearity and Comparative Bioavailability of a Single Oral Dose of 0.5 mg, 1 mg and 2.5 mg UT-15C (Treprostinil Diethanolamine) SR Tablets in Healthy Volunteers in the Fed StatePulmonary Arterial HypertensionDrug: Treprostinil diethanolamineUnited TherapeuticsNULLCompleted18 Years55 YearsBoth36Phase 1United States
31NCT01165476
(ClinicalTrials.gov)
July 201015/7/2010Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent FacilitiesAn Evaluation of the Comparative Bioavailability of a Single Oral Dose of 1mg UT-15C (Treprostinil Diethanolamine) SR Tablets Manufactured by Two Independent Facilities Administered to Healthy Volunteers in the Fed StatePulmonary Arterial HypertensionDrug: Treprostinil diethanolamineUnited TherapeuticsNULLCompleted18 Years55 YearsBoth64Phase 1United States
32NCT01131845
(ClinicalTrials.gov)
May 201010/5/2010The Effect of Renal Impairment on the Pharmacokinetics of Oral TreprostinilAn Evaluation of the Pharmacokinetics and Safety of a Single Dose of UT-15C SR (Treprostinil Diethanolamine) in Subjects With Renal Impairment.Pulmonary Arterial Hypertension;Renal DysfunctionDrug: UT-15C SR (treprostinil diethanolamine)United TherapeuticsNULLCompleted18 Years79 YearsBoth16Phase 1United States
33EUCTR2009-009366-13-PT
(EUCTR)
05/03/201003/11/2009A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Portugal;Germany;United Kingdom;Netherlands;Belgium;France;Spain;Italy;Austria;Sweden
34EUCTR2006-000804-18-SE
(EUCTR)
28/01/201003/12/2009An extension studyof UT-15C tablet in subjects with high blood pressure in the artery that carries blood to the lungsAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)
MedDRA version: 13.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
900Phase 3Portugal;Spain;Ireland;Austria;Israel;United Kingdom;Italy;France;Mexico;Puerto Rico;Belgium;Netherlands;Germany;Sweden
35NCT01148836
(ClinicalTrials.gov)
January 201019/3/2010Coenzyme Q-10 and Pulmonary Arterial HypertensionCoenzyme Q-10 in the Treatment of Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDietary Supplement: Coenzyme Q-10 in Pulmonary Hypertension subjects;Dietary Supplement: Coenzyme Q-10 in Normal Control subjectsThe Cleveland ClinicNULLCompleted18 Years55 YearsAll18N/AUnited States
36EUCTR2009-009366-13-SE
(EUCTR)
17/12/200922/10/2009A study to assess how safe and effective an oral UT-15C tablet is when given to subjects with high blood pressure in the artery that carries blood to the lungsA 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Portugal;Germany;Netherlands;France;Italy;Austria;Sweden;Israel;United Kingdom;Mexico;Belgium;Puerto Rico;Spain
37EUCTR2009-009366-13-FR
(EUCTR)
26/11/200906/11/2009A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Phase 3Portugal;France;Spain;Belgium;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
38EUCTR2009-009366-13-ES
(EUCTR)
18/11/200924/09/2009Estudio internacional, multicéntrico, aleatorizado, doble ciego y controlado con placebo de 16 semanas de duración sobre la eficacia y la seguridad de UT-15C por vía oral en comprimidos de liberación lenta en pacientes con hipertensión arterial pulmonarA 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2Estudio internacional, multicéntrico, aleatorizado, doble ciego y controlado con placebo de 16 semanas de duración sobre la eficacia y la seguridad de UT-15C por vía oral en comprimidos de liberación lenta en pacientes con hipertensión arterial pulmonarA 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Hipertensión Arterial PulmonarPulmonary Arterial Hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Product Name: treprostinil dietanolamina
Product Code: UT-15C SR
INN or Proposed INN: treprostinil dietanolamina
Product Name: treprostinil dietanolamina
Product Code: UT-15C
INN or Proposed INN: treprostinil dietanolamina
Product Name: treprostinil dietanolamina
Product Code: UT-15C
INN or Proposed INN: treprostinil dietanolamina
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Phase 3France;Portugal;Belgium;Spain;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
39EUCTR2009-009366-13-IT
(EUCTR)
17/11/200911/12/2009A 16-Week, International, Multicenter, Double-Blind, Randomized,Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C SustainedRelease Tablets in Subjects with Pulmonary ArterialHypertension - Freedom CA 16-Week, International, Multicenter, Double-Blind, Randomized,Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C SustainedRelease Tablets in Subjects with Pulmonary ArterialHypertension - Freedom C Pulmonary Arterial Hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10064911
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
UNITED THERAPEUTICSNULLNot RecruitingFemale: yes
Male: yes
300Portugal;Germany;United Kingdom;Netherlands;Belgium;France;Spain;Italy;Austria;Sweden
40EUCTR2009-009366-13-NL
(EUCTR)
04/11/200918/08/2009A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Portugal;Germany;United Kingdom;Netherlands;Belgium;France;Spain;Italy;Austria;Sweden
41EUCTR2009-009366-13-BE
(EUCTR)
23/10/200904/09/2009A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300France;Portugal;Spain;Belgium;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
42EUCTR2009-009366-13-AT
(EUCTR)
22/10/200923/09/2009A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Portugal;Germany;United Kingdom;Netherlands;Belgium;France;Spain;Italy;Austria;Sweden
43EUCTR2009-009366-13-GB
(EUCTR)
02/09/200907/08/2009A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Portugal;Germany;United Kingdom;Netherlands;Belgium;France;Spain;Italy;Austria;Sweden
44NCT00963027
(ClinicalTrials.gov)
September 200919/8/2009Effect of Esomeprazole on the Pharmacokinetics of Oral TreprostinilAn Evaluation of Single Dose UT-15C SR (Treprostinil Diethanolamine) Pharmacokinetics Following Repeated Dosing With the Proton Pump Inhibitor Esomeprazole in Healthy Adult VolunteersHypertension, Pulmonary;Pulmonary Arterial HypertensionDrug: Treprostinil diethanolamine;Drug: EsomeprazoleUnited TherapeuticsNULLCompleted18 Years55 YearsBoth30Phase 1United States
45NCT00963001
(ClinicalTrials.gov)
September 200919/8/2009Effect of Food on the Pharmacokinetics of Oral TreprostinilEffect of Different Meal Types on the Pharmacokinetics of a Single 1 mg Oral Dose of UT-15C (Treprostinil Diethanolamine) Sustained Release Tablets in Healthy VolunteersHypertension, Pulmonary;Pulmonary Arterial HypertensionDrug: Treprostinil diethanolamine;Other: Standardized mealsUnited TherapeuticsNULLCompleted18 Years55 YearsBoth32Phase 1United States
46EUCTR2006-000804-18-DE
(EUCTR)
10/04/200812/12/2007An extension study of UT-15C tablet in subjects with high blood pressure inthe artery that carries blood to the lungsAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use) or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or3) Collagen Vascular Disease (CVD)4) Human Immunosufficiency Virus (HIV)
MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
900Phase 3Portugal;Spain;Ireland;Austria;Israel;United Kingdom;Italy;France;Mexico;Puerto Rico;Belgium;Germany;Netherlands;Sweden
47EUCTR2006-000800-17-DE
(EUCTR)
02/04/200819/05/2008A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease, or4) HIV
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300United Kingdom;Germany;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria
48EUCTR2006-000800-17-IT
(EUCTR)
27/08/200710/05/2007A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CA 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C Pulmonary Arterial Hypertension (PAH)
MedDRA version: 9.1;Level: LLT;Classification code 10037400;Term: Pulmonary hypertension
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil Diethanolamine
UNITED THERAPEUTICSNULLNot RecruitingFemale: yes
Male: yes
300Germany;United Kingdom;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria
49EUCTR2006-000801-50-NL
(EUCTR)
03/07/200702/04/2007A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-MA 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-M Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease (CVD), or 4) Human Immunodeficiency virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil Diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
150Phase 3France;Belgium;Austria;Netherlands;Italy
50EUCTR2006-000800-17-NL
(EUCTR)
19/06/200701/12/2006A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease, or4) HIV
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Germany;United Kingdom;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria
51EUCTR2006-000804-18-NL
(EUCTR)
19/06/200701/12/2006An extension studyof UT-15C tablet in subjects with high blood pressure in the artery that carries blood to the lungsAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)
MedDRA version: 16.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
900Phase 3Portugal;Spain;Ireland;Austria;Israel;United Kingdom;Italy;France;Mexico;Puerto Rico;Belgium;Netherlands;Germany;Sweden
52EUCTR2006-000801-50-IT
(EUCTR)
12/06/200721/06/2007A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-MA 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-M Pulmonary Arterial Hypertension (PAH)
MedDRA version: 6.1;Level: PT;Classification code 10037400
Product Name: treprostinil
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: treprostinil
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
UNITED THERAPEUTICSNULLNot RecruitingFemale: yes
Male: yes
150Netherlands;Belgium;France;Italy;Austria
53EUCTR2006-000804-18-FR
(EUCTR)
11/06/200719/01/2007An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
450Phase 3Portugal;France;Spain;Belgium;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
54EUCTR2006-000804-18-ES
(EUCTR)
29/05/200702/03/2010Estudio abierto de ampliación con UT-15C LP en sujetos con hipertensión arterial pulmonarAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTEstudio abierto de ampliación con UT-15C LP en sujetos con hipertensión arterial pulmonarAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT HAP idiopática o familiar incluyendo HAP asociada a:1) Uso de un inhibidor del apetito2) Cortocircuito sistémico-pulmonar congénito corregido (corrección = 5 años)3) HAP asociada a enfermedad del tejido conjuntivo vascular4) VIH.
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Dietanolamina de treprostinilo
Product Code: UT-15C LP
INN or Proposed INN: Dietanolamina de treprostinilo
Product Name: Dietanolamina de treprostinilo
Product Code: UT-15C LP
INN or Proposed INN: Dietanolamina de treprostinilo
Product Name: Dietanolamina de treprostinilo
Product Code: UT-15C LP
INN or Proposed INN: Dietanolamina de treprostinilo
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
450Portugal;France;Belgium;Spain;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
55EUCTR2006-000800-17-ES
(EUCTR)
29/05/200702/03/2010Estudio internacional, multicéntrico, doble ciego, aleatorizado, controlado con placebo y de 16 semanas de duración para comparar la eficacia y la seguridad de UT-15C en comprimidos orales de liberación prolongada en combinación con un antagonista del receptor de la endotelina y/o con un inhibidor de la fosfodiesterasa-5 en sujetos con hipertensión arterial pulmonarA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CEstudio internacional, multicéntrico, doble ciego, aleatorizado, controlado con placebo y de 16 semanas de duración para comparar la eficacia y la seguridad de UT-15C en comprimidos orales de liberación prolongada en combinación con un antagonista del receptor de la endotelina y/o con un inhibidor de la fosfodiesterasa-5 en sujetos con hipertensión arterial pulmonarA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C HAP idiopática o familiar incluyendo HAP asociada a:1) Uso de un inhibidor del apetito2) Corticircuito sistémico-pulmonar congénito corregido (corrección = 5 años)3) HAP asociada a enfermedad del tejido conjuntivo vascular4) HIV
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Dietanolamina de treprostinilo
Product Code: UT-15C LP
INN or Proposed INN: Dietanolamina de treprostinilo
Product Name: Dietanolamina de treprostinilo
Product Code: UT-15C LP
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Phase 3France;Belgium;Spain;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom
56EUCTR2006-000800-17-FR
(EUCTR)
21/05/200719/01/2007A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease (CVD), or 4) Human Immunodeficiency virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Phase 3France;Spain;Belgium;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom
57EUCTR2006-000801-50-FR
(EUCTR)
21/05/200719/01/2007A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-MA 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-M Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease (CVD), or 4) Human Immunodeficiency virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
150Phase 3France;Belgium;Austria;Netherlands;Italy
58EUCTR2006-000804-18-GB
(EUCTR)
04/05/200722/11/2006An extension study of UT-15C tablet in subjects with high blood pressure in the artery that carries blood to the lungsAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)
MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
900Phase 3Portugal;Spain;Ireland;Austria;Israel;United Kingdom;Italy;France;Mexico;Puerto Rico;Belgium;Netherlands;Germany;Sweden
59EUCTR2006-000804-18-BE
(EUCTR)
23/04/200725/01/2007An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)
MedDRA version: 13.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
900Phase 3Portugal;France;Spain;Belgium;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
60EUCTR2006-000801-50-AT
(EUCTR)
19/02/200717/01/2007A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-MA 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-M Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease (CVD), or 4) Human Immunodeficiency virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
150Netherlands;Belgium;France;Italy;Austria
61EUCTR2006-000804-18-AT
(EUCTR)
19/02/200717/01/2007An extension study of UT-15C tablet in subjects with high blood pressure inthe artery that carries blood to the lungsAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use) or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or3) Collagen Vascular Disease (CVD)4) Human Immunosufficiency Virus (HIV)
MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
900Phase 3Portugal;Spain;Ireland;Austria;Israel;United Kingdom;Italy;France;Mexico;Puerto Rico;Belgium;Netherlands;Germany;Sweden
62EUCTR2006-000800-17-IE
(EUCTR)
15/02/200713/11/2006A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease (CVD), or 4) Human Immunodeficiency virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Germany;United Kingdom;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria
63EUCTR2006-000804-18-IE
(EUCTR)
15/02/200709/11/2006An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTAn Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
450Phase 3Portugal;France;Spain;Belgium;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
64EUCTR2006-000800-17-AT
(EUCTR)
19/01/200717/01/2007A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use, or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or3) Collagen Vascular Disease, or4) HIV
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300Germany;United Kingdom;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria
65EUCTR2006-000800-17-GB
(EUCTR)
18/01/200722/11/2006A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with: 1) Appetite suppressant use, or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years), or 3) Collagen Vascular Disease (CVD), or 4) Human Immunodeficiency virus (HIV)
MedDRA version: 8.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension
Product Name: Treprostinil Diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprosinil Diethanolamine
Product Code: UT-15C-SR
INN or Proposed INN: Treprostinil diethanolamine
Product Name: Treprosinil Diethanolamine
Product Code: UT-15C-SR
INN or Proposed INN: Treprostinil diethanolamine
United Therapeutics CorporationNULLNot Recruiting Female: yes
Male: yes
300 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;Spain;Belgium;Ireland;Austria;Germany;Netherlands;Italy;United Kingdom
66NCT01027949
(ClinicalTrials.gov)
May 20064/12/2009An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial HypertensionAn Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Treprostinil diethanolamineUnited TherapeuticsNULLActive, not recruiting12 YearsN/AAll900Phase 3United States;Australia;Austria;Belgium;Canada;France;Germany;India;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Spain;Sweden;United Kingdom;Czech Republic
67EUCTR2009-009366-13-DE
(EUCTR)
23/09/2009A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension - FREEDOM-C2 Pulmonary Arterial Hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Product Name: treprostinil diethanolamine
Product Code: UT-15C SR
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
Product Name: treprostinil diethanolamine
Product Code: UT-15C
INN or Proposed INN: treprostinil diethanolamine
United Therapeutics CorporationNULLNot RecruitingFemale: yes
Male: yes
300France;Portugal;Spain;Belgium;Austria;Netherlands;Germany;Italy;United Kingdom;Sweden

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05743374
(ClinicalTrials.gov)
February 202314/2/2023Micronutrient and Additive Modifications May Optimize Diet To HealthMicronutrient and Additive Modifications May Optimize Diet To HealthUlcerative Colitis;Diet Habit;Microbial ColonizationOther: Normal diet;Dietary Supplement: E400 eliminationRegion SkaneNULLNot yet recruiting18 YearsN/AAll70N/ASweden
2NCT05507931
(ClinicalTrials.gov)
February 202317/8/2022Broccoli Sprouts for Mild Ulcerative ColitisA Pilot Feasibility Study to Develop a Broccoli Sprouts-enriched Diet in the Management of Ulcerative ColitisUlcerative Colitis;Ulcerative Colitis Chronic MildDietary Supplement: 1 Serving of broccoli sprouts;Dietary Supplement: 3 Servings of broccoli sproutsUniversity of MichiganUniversity of MaineNot yet recruiting18 YearsN/AAll40N/AUnited States
3NCT05561738
(ClinicalTrials.gov)
January 1, 202313/9/2022Nicotinamide Riboside in Ulcerative ColitisNicotinamide Riboside in Ulcerative ColitisUlcerative ColitisDietary Supplement: Nicotinamide Riboside Chloride;Dietary Supplement: Placebo;Other: Standard of CareUniversity of PittsburghCrohn's and Colitis FoundationNot yet recruitingN/A18 YearsAll40N/AUnited States
4NCT05579483
(ClinicalTrials.gov)
December 20224/10/2022Prediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome SignaturesPrediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome SignaturesUlcerative ColitisDietary Supplement: Prebiotics;Dietary Supplement: PlaceboWageningen UniversityWinclove Probiotics B.V.;China Scholarship CouncilNot yet recruiting18 Years65 YearsAll60N/ANetherlands
5NCT05539625
(ClinicalTrials.gov)
September 20224/8/2022Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative ColitisMitochondrial Antioxidant Therapy to Resolve Inflammation in Ulcerative Colitis (Mini-MARVEL): A Phase 2b Feasibility Randomised Placebo Controlled Trial of Oral MitoQ in Mild-tomoderately Active Paediatric UCUlcerative ColitisDietary Supplement: MitoQ;Other: PlaceboUniversity of EdinburghThe Jon Moulton Charity Trust;MitoQNot yet recruiting6 Years17 YearsAll120Phase 2NULL
6NCT05652621
(ClinicalTrials.gov)
July 31, 20229/9/2022Efficacy of Probiotics in Patients With IBDClinical Efficacy and Mechanism of Probiotics in the Adjuvant Treatment of Ulcerative Colitis and Irritable Bowel SyndromeUlcerative Colitis;Irritable Bowel SyndromeDietary Supplement: probioticsThe First Affiliated Hospital of Xinxiang Medical CollegeNULLRecruiting18 Years80 YearsAll200N/AChina
7NCT05761327
(ClinicalTrials.gov)
June 3, 202211/2/2023Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative ColitisInvestigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative ColitisUlcerative ColitisOther: Mediterranean Diet;Dietary Supplement: Curcumin Supplementation;Dietary Supplement: Resveratrol SupplementationArdahan UniversityNULLRecruiting18 Years70 YearsAll45N/ATurkey
8NCT04276740
(ClinicalTrials.gov)
May 31, 202212/2/2020MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative ColitisMitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis (MARVEL): A Randomised Placebo-controlled Trial on Oral MitoQ in Moderate UCUlcerative Colitis FlareDietary Supplement: MitoQ;Other: PlaceboUniversity of EdinburghJP Moulton Charitable Foundation;MitoQNot yet recruiting18 YearsN/AAll206Phase 2NULL
9NCT04749576
(ClinicalTrials.gov)
December 15, 20209/12/2020Saffron as Anti Inflammatory Agent In Patients With Inflammatory Bowel DiseaseEfficacy of Nutritional Saffron Supplement As An Anti Inflammatory Agent In Patients With Inflammatory Bowel DiseaseUlcerative ColitisDietary Supplement: saffron supplement for IBDHoward UniversityNULLRecruiting18 Years80 YearsAll100N/AUnited States
10NCT04505410
(ClinicalTrials.gov)
November 18, 20205/8/2020Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative ColitisA Randomized Control Study to Examine the Influence of a Healthy Diet on Moderate to Severe Ulcerative Colitis Patients Undergoing Second Line Induction With Biological Medications Tofacitinib, Ustekinumab or VedolizumabUlcerative ColitisDrug: Tofacitinib;Other: Fast Mimicking Diet;Drug: Ustekinumab induction;Drug: Infliximab inductionUniversity of MiamiPfizerRecruiting18 YearsN/AAll76Phase 3United States
11EUCTR2018-005086-39-BG
(EUCTR)
27/10/202025/06/2020A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative ColitisA Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors.
MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: BT-11 500 mg
Product Code: BT-11
INN or Proposed INN: to be requested
Other descriptive name: BT-11
Product Name: BT-11 1000mg
Product Code: BT-11
INN or Proposed INN: to be requested
Other descriptive name: BT-11
Landos Biopharma Inc.NULLNot RecruitingFemale: yes
Male: yes
195Phase 2United States;Serbia;Belarus;Hungary;Poland;Ukraine;Croatia;Russian Federation;Georgia;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
12JPRN-UMIN000041972
2020/10/0101/10/2020Clinical trial on the effects of dietary intake of sulforaphane-rich broccoli sprouts on severity of ulcerative colitis.Clinical trial on the effects of dietary intake of sulforaphane-rich broccoli sprouts on severity of ulcerative colitis. - BS-UC-2020 ulcerative colitisBroccoli Sprouts (20 g/day, 8 weeks)
Alfalfa Sprouts (20 g/day, 8 weeks)
University of TsukubaNULLRecruiting20years-oldNot applicableMale and Female50Not selectedJapan
13NCT04225819
(ClinicalTrials.gov)
October 1, 20203/1/2020Adjunctive Treatment With Vitamin D3 in Patients With Active IBDAdjunctive Treatment With Vitamin D3 in Patients With Active IBD (ACTIVATED): A Randomized, Double-blind, Placebo-controlled TrialIBD;Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Vitamin D3 DeficiencyDietary Supplement: Vitamin D3;Other: PlaceboMassachusetts General HospitalNULLRecruiting18 YearsN/AAll100N/AUnited States
14NCT04188990
(ClinicalTrials.gov)
June 15, 20202/12/2019Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related MalnutritionEvaluation of the Effectiveness and Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related MalnutritionPancreatitis, Acute;Crohn Disease;Ulcerative Colitis;Inflammatory Bowel Diseases;Pancreatic Cancer;Esophagus Cancer;Gastric Cancer;Colorectal CancerDietary Supplement: Nutritional dietary intervention;Dietary Supplement: By demand;Dietary Supplement: Usual current careHospital Galdakao-UsansoloNULLActive, not recruiting18 YearsN/AAll900N/ASpain
15NCT04332328
(ClinicalTrials.gov)
April 1, 202031/3/2020Study of Demographic and Dietary Profile in Patients With Ulcerative Colitis in Upper EgyptStudy of Demographic and Dietary Profile in Patients With Ulcerative Colitis in Upper EgyptDiet in Ulcerative Colitis PatientsDietary Supplement: DietAssiut UniversityNULLNot yet recruitingN/AN/AAll50NULL
16NCT03980405
(ClinicalTrials.gov)
April 1, 20205/6/2019Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative ColitisCombination Therapy With Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative Colitis: A Single Blinded, International Randomized Controlled TrialUlcerative ColitisDietary Supplement: Group 1- Control Diet;Dietary Supplement: Group 2- UCD DietProf. Arie LevineNULLTerminated10 Years19 YearsAll12N/AIsrael
17NCT02277223
(ClinicalTrials.gov)
March 1, 202025/10/2014Curcumin in Pediatric Ulcerative ColitisCurcumin for Induction and Maintenance Therapy in Pediatric Ulcerative ColitisUlcerative ColitisDietary Supplement: Curcumin;Drug: PlaceboSchneider Children's Medical Center, IsraelNULLWithdrawn6 Years18 YearsAll0Phase 3Israel
18EUCTR2019-003220-21-GB
(EUCTR)
26/02/202012/12/2019Management of diarrhoea in ulcerative colitis: multi-arm multi stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE.Management of diarrhoea in ulcerative colitis: multi-arm multi-stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE. - MODULATE Diarrhoea in patients with stable ulcerative colitis.
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856
MedDRA version: 20.1;Classification code 10033007;Term: Other ulcerative colitis;Classification code 10066557;Term: Chronic diarrhoea;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Amitriptyline
Product Name: Amitriptyline
INN or Proposed INN: Amitriptyline hydrochloride
Product Name: Ondansetron
INN or Proposed INN: Ondansetron hydrochloride dihydrate
Product Name: Loperamide
INN or Proposed INN: loperamide hydrochloride
University of LeedsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
491Phase 2;Phase 3United Kingdom
19NCT04241029
(ClinicalTrials.gov)
February 25, 202017/1/2020Boosting Biologics in UCBoosting Biologics in Ulcerative ColitisUlcerative Colitis;Inflammatory Bowel DiseasesDietary Supplement: IDOFORM®TravelOslo University HospitalHelse Sor-OstRecruiting18 Years75 YearsAll20Phase 1Norway
20NCT03998488
(ClinicalTrials.gov)
January 31, 202024/6/2019Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative ColitisA Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative ColitisUlcerative Colitis;Inflammatory Bowel DiseasesDrug: Fecal Microbiota Transplantation;Dietary Supplement: Psyllium Husk PowderWeill Medical College of Cornell UniversityCrohn's and Colitis FoundationRecruiting18 Years89 YearsAll135Phase 2United States
21NCT05656391
(ClinicalTrials.gov)
December 16, 20191/12/2022Impact of Bread Diet on Intestinal Dysbiosis and Irritable Bowel Syndrome Symptoms in Quiescent Ulcerative ColitisImpact of Bread Diet on Intestinal Dysbiosis and Irritable Bowel Syndrome Symptoms in Quiescent Ulcerative Colitis: A Pilot StudyUlcerative Colitis in RemissionDietary Supplement: Treatment vs control breadInstitut d'Investigació Biomèdica de Girona Dr. Josep TruetaNULLCompleted18 YearsN/AAll31N/ASpain
22EUCTR2018-005086-39-HR
(EUCTR)
16/12/201917/01/2020A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative ColitisA Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors.
MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: BT-11 500 mg
Product Code: BT-11
INN or Proposed INN: to be requested
Other descriptive name: BT-11
Product Name: BT-11 1000mg
Product Code: BT-11
INN or Proposed INN: to be requested
Other descriptive name: BT-11
Landos Biopharma Inc.NULLNot RecruitingFemale: yes
Male: yes
195Phase 2Belarus;Serbia;United States;Ukraine;Russian Federation;Hungary;Canada;Poland;Croatia;Bulgaria;Georgia;Moldova, Republic of;Bosnia and Herzegovina
23EUCTR2018-005086-39-HU
(EUCTR)
28/10/201908/04/2019A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative ColitisA Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors.
MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: BT-11
INN or Proposed INN: to be requested
Product Code: BT-11
INN or Proposed INN: to be requested
Landos Biopharma Inc.NULLNot RecruitingFemale: yes
Male: yes
195Phase 2United States;Serbia;Belarus;Hungary;Poland;Ukraine;Croatia;Bulgaria;Russian Federation;Georgia;Moldova, Republic of;Bosnia and Herzegovina
24EUCTR2018-005086-39-PL
(EUCTR)
07/10/201906/05/2019A Study to Evaluate Efficacy and Safety of BT-11 product oral tablets in Mild to Moderate Ulcerative ColitisA Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors.
MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: BT-11 500 mg
Product Code: BT-11
INN or Proposed INN: to be requested
Other descriptive name: BT-11
Product Name: BT-11 1000mg
Product Code: BT-11
INN or Proposed INN: to be requested
Other descriptive name: BT-11
Landos Biopharma Inc.NULLNot RecruitingFemale: yes
Male: yes
195Phase 2Russian Federation;Hungary;United States;Moldova, Republic of;Ukraine;Poland;Georgia;Belarus;Serbia;Bulgaria;Bosnia and Herzegovina;Croatia
25NCT04006977
(ClinicalTrials.gov)
October 20191/7/2019Multistrain Probiotics Reduces UC Depression and Anxiety ScoresMultistrain Probiotic Product (De Simone Formulation) Reduces Depression and Anxiety Scores: a Randomized Pilot Study in Patients With Ulcerative ColitisUlcerative ColitisDietary Supplement: a multistrain probiotic product (DSF);Dietary Supplement: PlaceboXijing Hospital of Digestive DiseasesMENDES SANot yet recruiting18 Years65 YearsAll60N/AChina
26NCT04102852
(ClinicalTrials.gov)
September 30, 201917/9/2019Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC PatientsThe Role of Lactobacillus Rhamnosus GG (ATCC 53103) in the Modulation of the Inflammatory Process in the Mucosa of Ulcerative Colitis (UC) Patients With Mild-moderate Clinical ActivityUlcerative Colitis Chronic Mild;Ulcerative Colitis Chronic ModerateDietary Supplement: Lactobacillus rhamnosus GG ATCC 53103San Giovanni Addolorata HospitalOnlus S. AndreaCompleted18 Years65 YearsAll76Phase 1/Phase 2Italy
27NCT03847467
(ClinicalTrials.gov)
September 20, 201912/2/2019Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF TherapyPilot and Feasibility Study of 2'-FL as a Dietary Supplement in Pediatric and Young Adult IBD Patients Receiving Stable Maintenance Anti-TNF TherapyInflammatory Bowel Diseases;Crohn Disease;Ulcerative ColitisDrug: 2'-Fucosyllactose;Other: PlaceboChildren's Hospital Medical Center, CincinnatiBroad Institute;University of Cincinnati;Connecticut Children's Medical CenterRecruiting11 Years25 YearsAll216Phase 1/Phase 2United States
28NCT03941418
(ClinicalTrials.gov)
June 1, 20195/5/2019Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn DiseaseImpact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn DiseaseUlcerative Colitis;Crohn DiseaseDietary Supplement: Boulardii;Dietary Supplement: PlaceboUniversity Clinic Dr Dragisa Misovic-DedinjeUniversity Clinic ZvezdaraNot yet recruiting18 Years80 YearsAll150N/ANULL
29NCT03720002
(ClinicalTrials.gov)
May 29, 201921/10/2018HF2 Therapy in the Treatment of Active Ulcerative ColitisHF2 Therapy in the Treatment of Active Ulcerative Colitis:Ulcerative ColitisDietary Supplement: HF2Sheba Medical CenterNULLRecruiting18 Years70 YearsAll52Phase 1/Phase 2Greece;Israel
30NCT02201758
(ClinicalTrials.gov)
December 201818/7/2014Flaxseed Lignan-Enriched Complex (FLC) for the Treatment of Patients With Ulcerative Colitis (UC): A Pilot AssessmentFlaxseed Lignan-enriched Complex (FLC) for the Treatment of Patients With Mild to Moderately Severe Ulcerative Colitis (UC): A Pilot Assessment.Ulcerative ColitisDietary Supplement: Flaxseed lignan-enriched complex (FLC);Other: PlaceboUniversity of SaskatchewanRoyal University Hospital FoundationUnknown status18 YearsN/AAll56Phase 2Canada
31NCT02469220
(ClinicalTrials.gov)
July 1, 20188/6/2015Diet Treatment of Patients With Ulcerative Colitis in RemissionDiet Treatment of Patients With Ulcerative Colitis in RemissionUlcerative ColitisDietary Supplement: Low FODMAP;Dietary Supplement: Standardized FODMAPVendsyssel HospitalNULLCompleted18 Years70 YearsAll19N/ADenmark
32NCT04329481
(ClinicalTrials.gov)
June 12, 201829/3/2020The Effect of Mycobiome Supplementation on Gastrointestinal Symptoms in IBD PatientsThe Effect of Mycobiome Supplementation on Gastrointestinal Symptoms in IBD PatientsUlcerative Colitis;Crohn Disease;Inflammatory Bowel DiseasesDietary Supplement: Mycodigest supplementTel-Aviv Sourasky Medical CenterNULLRecruiting18 Years70 YearsAll100N/AIsrael
33NCT03594708
(ClinicalTrials.gov)
April 30, 201819/1/2018Immunonutrition in Ulcerative ColitisImpact of Immunonutrition Supplementation Combining Fermentable Fiber, Omega-3 Fatty Acids, Vitamin D, Vitamin E, and Zinc on Intestinal Inflammation, Gut Microbial Activity, and Severity of Symptoms in Ulcerative Colitis PatientsUlcerative ColitisDietary Supplement: Nutrition supplement;Dietary Supplement: Placebo supplementBaptist Memorial Health Care CorporationNULLUnknown status18 YearsN/AAll30N/AUnited States
34NCT03444311
(ClinicalTrials.gov)
March 8, 20188/2/2018Combined Nutritional Therapies for the Treatment of Ulcerative ColitisDevelopment of Combined Nutritional Therapies for the Treatment of Ulcerative Colitis Through the Increase of the Biodiversity of the Microbiota.Colitis, UlcerativeDietary Supplement: A: 1 dosis;Dietary Supplement: B: 2 dosisAB Biotics, SANULLTerminated18 Years65 YearsAll12N/ASpain
35NCT03309865
(ClinicalTrials.gov)
December 25, 20177/10/2017Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.A Pilot Study Evaluating the Synergistic Effect of Vedolizumab in Conjunction With Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis.Ulcerative Colitis;Dietary ModificationDietary Supplement: semi-vegetarian diet;Drug: Vedolizumab InjectionMayo ClinicNULLWithdrawn18 YearsN/AAll0Early Phase 1United States
36NCT03266484
(ClinicalTrials.gov)
November 13, 201725/8/2017Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel DiseaseEffect of Dietary Therapy With a Probiotic Mixture on the Gut Microbiome and Fatigue Symptoms in Patients With Quiescent Inflammatory Bowel Disease - A Clinical TrialInflammatory Bowel Diseases;Crohn Disease;Ulcerative ColitisDietary Supplement: Probiotic Mixture;Dietary Supplement: PlaceboMassachusetts General HospitalWinclove Bio Industries BVActive, not recruiting18 Years75 YearsAll100N/AUnited States
37NCT03122613
(ClinicalTrials.gov)
June 19, 20177/4/2017Curcumin for Prevention of Relapse in Patients With Ulcerative ColitisA Double-blind, Randomized, Placebo-Controlled Trial of Curcumin Versus Placebo for Prevention of Relapse in Patients With Ulcerative ColitisUlcerative Colitis in RemissionDietary Supplement: Curcumin;Drug: PlaceboChinese University of Hong KongNULLTerminated18 YearsN/AAll29N/AHong Kong
38NCT03415711
(ClinicalTrials.gov)
April 28, 20175/1/2018PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative ColitisA Double-blind, Randomized, Placebo-controlled, Single-center, Dose-finding, Pilot Study Evaluating the Efficacy of VSL#3® in the Maintenance of Clinical and Endoscopic Remission of Mild-to-moderate UCUlcerative ColitisDietary Supplement: VSL#3®;Drug: Mesalamine;Drug: PlaceboVSL PharmaceuticalsActial Farmaceutica S.r.l.Terminated18 Years85 YearsAll14N/AItaly
39NCT03798210
(ClinicalTrials.gov)
January 1, 20177/1/2019Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative ColitisThe Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative ColitisUlcerative Colitis FlareDietary Supplement: Lactobacillus reuteri;Dietary Supplement: PlaceboUppsala UniversityNULLRecruiting18 Years80 YearsAll40Phase 2Sweden
40NCT03136419
(ClinicalTrials.gov)
October 31, 20165/4/2017Microbiota and Immune microEnvironment in PouchitisMicrobiota and Immune microEnvironment in Pouchitis: Randomized Controlled Trial Oral Administration of Lactobacillus Casei DG After Ileostomy Closure in Ileal Pouch MucosaPouchitis;Ulcerative Colitis;Ileal PouchDietary Supplement: Lactobacillus casei DG;Dietary Supplement: PlaceboUniversity of PadovaNULLRecruiting18 Years100 YearsAll32N/AItaly
41NCT02825914
(ClinicalTrials.gov)
September 1, 201630/6/2016CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)Colitis, Ulcerative;Inflammatory Bowel DiseasesDietary Supplement: Casein glycomacropeptide (CGMP);Dietary Supplement: PlaceboUniversity of AarhusNULLCompleted18 YearsN/AAll80N/ADenmark
42NCT02865707
(ClinicalTrials.gov)
August 201612/7/2016Ulcerative Colitis Relapse Prevention by PrebioticsPrevention of Ulcerative Colitis by Prebiotics: Efficacy and Protective MechanismsUlcerative ColitisDietary Supplement: Synergy-1;Dietary Supplement: MaltodextrinUniversity of AlbertaUniversity of British ColumbiaCompleted18 Years75 YearsAll89N/ACanada
43NCT02683759
(ClinicalTrials.gov)
February 201610/2/2016Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative ColitisThe Efficacy and Tolerability of Bio-Enhanced Curcumin in Maintaining Remission in Patients With Ulcerative ColitisUlcerative ColitisDietary Supplement: Bio-enhanced Curcumin Soft Gelatin Capsule;Drug: 5-Aminosalicyclic acidAsian Institute of Gastroenterology, IndiaNULLRecruiting18 Years70 YearsBoth50Phase 3India
44NCT02683733
(ClinicalTrials.gov)
February 201610/2/2016Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative ColitisThe Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative ColitisUlcerative ColitisDietary Supplement: Bio-enhanced Curcumin Soft Gelatin Capsule;Drug: 5-Aminosalicylic acidAsian Institute of Gastroenterology, IndiaNULLRecruiting18 Years70 YearsBoth50Phase 3India
45NCT02345733
(ClinicalTrials.gov)
September 1, 201519/1/2015Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative ColitisUse of a Novel Diet (UC DIET) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot StudyUlcerative Colitis (UC)Other: Ulcerative Colitis Diet;Drug: Antibiotic cocktailProf. Arie LevineNULLCompleted8 Years19 YearsAll20Phase 4United States;Canada;Israel
46NCT02084550
(ClinicalTrials.gov)
September 20155/3/2014Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative ColitisAmino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis: a Randomized, Assessor-blinded, Placebo-controlled TrialUlcerative ColitisDietary Supplement: Vaminolac;Other: SalineAarhus University HospitalNULLActive, not recruiting18 Years50 YearsAll8N/ADenmark
47NCT02361957
(ClinicalTrials.gov)
November 201415/1/2015The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis PatientsThe Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis PatientsUlcerative ColitisDietary Supplement: Ecologic 825;Dietary Supplement: PlaceboWageningen UniversityNULLSuspended18 Years65 YearsBoth40N/ANetherlands
48NCT02217722
(ClinicalTrials.gov)
October 201420/7/2014Use of the Ulcerative Colitis Diet for Induction of RemissionAn Open Label Non Randomized Pilot Study: Use of the Ulcerative Colitis Diet for Induction of Remission.Ulcerative Colitis (UC)Other: Ulcerative Colitis Diet;Drug: Antibiotic cocktailProf. Arie LevineNULLTerminated5 Years18 YearsBoth9N/AIsrael
49NCT02179372
(ClinicalTrials.gov)
June 201429/6/2014Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel DiseasesModulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel DiseasesUlcerative Colitis;Crohn's DiseaseDietary Supplement: Eicosapentaenoic acid;Dietary Supplement: Medium chain fatty acid (placebo)Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola MalpighiNULLCompleted18 Years80 YearsBoth60N/AItaly
50NCT02069561
(ClinicalTrials.gov)
January 201419/2/2014Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal CancerEffects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel DiseaseUlcerative ColitisDietary Supplement: Eicosapentaenoic AcidAzienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola MalpighiNULLCompleted18 Years70 YearsBoth25N/AItaly
51NCT01771224
(ClinicalTrials.gov)
January 201316/1/2013Effect of FAn-7 in UC ActivityEffect of Palmitoleic Acid (FAn-7) on Expression of HNF4? and Ulcerative Colitis (UC) ActivityInflammatory Bowel Disease;Ulcerative ColitisDietary Supplement: Palmitoleic acidNational Institute of Medical Sciences and Nutrition, Salvador ZubiranNULLRecruiting18 Years59 YearsBoth20Phase 0Mexico
52NCT01078935
(ClinicalTrials.gov)
December 20121/3/2010The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of InflammationThe Effect of Probiotics on Bowel DiseaseCrohn's Disease;Ulcerative ColitisDietary Supplement: probiotics;Dietary Supplement: placeboThe Baruch Padeh Medical Center, PoriyaMinistry of Health, IsraelNot yet recruiting18 Years80 YearsBoth100Phase 4NULL
53NCT01783119
(ClinicalTrials.gov)
August 201231/1/2013Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative ColitisEffect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative ColitisUlcerative ColitisDietary Supplement: Aloe Barbadensis Miller;Dietary Supplement: placebo waterNational Institute of Medical Sciences and Nutrition, Salvador ZubiranNULLRecruiting18 Years59 YearsBoth60Phase 0Mexico
54NCT01877577
(ClinicalTrials.gov)
April 201211/6/2013Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis DSupplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.Crohn's Disease (CD);Ulcerative Colitis (UC)Dietary Supplement: Vitamin D3University of California, San FranciscoNULLCompleted18 YearsN/ABoth30N/AUnited States
55NCT01496053
(ClinicalTrials.gov)
December 201115/12/2011Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective StudyUlcerative Colitis;Crohn's Disease;Inflammatory Bowel DiseaseDietary Supplement: AndoSan;Dietary Supplement: Sugar ExtractOslo University HospitalImmunoPharma ASCompleted18 Years60 YearsAll100Phase 2/Phase 3Norway
56NCT01320436
(ClinicalTrials.gov)
July 201121/3/2011Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative ColitisRandomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis PatientsUlcerative ColitisDietary Supplement: Curcumin;Drug: 5-aminosalicylic acidSheba Medical CenterNULLCompleted18 Years70 YearsBoth50Phase 3Israel
57NCT01772615
(ClinicalTrials.gov)
May 201117/1/2013Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli NissleActive Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli NissleUlcerative ColitisDrug: Ciprofloxacin;Dietary Supplement: E. coli NissleHvidovre University HospitalNULLCompleted18 YearsN/ABoth100Phase 4Denmark
58NCT01065571
(ClinicalTrials.gov)
January 20104/2/2010Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease ActivityEffects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease ActivityUlcerative ColitisDietary Supplement: carrageenan;Other: dietary intervention with no-carrageenan dietUniversity of Illinois at ChicagoThe Broad Foundation;University of ChicagoCompleted18 YearsN/AAll15N/AUnited States
59NCT00793130
(ClinicalTrials.gov)
November 200816/11/2008The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open LabelThe Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open LabelUlcerative ColitisDietary Supplement: ColtectTel-Aviv Sourasky Medical CenterNULLRecruiting18 Years75 YearsBoth30N/AIsrael
60NCT00751933
(ClinicalTrials.gov)
October 200811/9/2008Vaccines and Dietary Oats in the Treatment of Ulcerative ColitisA Controlled Study of Salmonella Ty21a and Cholera/ ETEC-vaccine and the Role of Oats in Daily Diet as a New Treatment in Patients With Mild or Moderate Ulcerative Colitis.Ulcerative ColitisBiological: Vaccine Vivotif + Vaccine Dukoral + oats;Biological: Vaccine Vivotif + Vaccine Dukoral;Dietary Supplement: Oats;Other: PlaceboHaukeland University HospitalHelse VestTerminated18 Years80 YearsAll3Phase 2Norway
61ChiCTR-TRC-08000145
2008-09-012008-08-25The study of the treatment and rehabilitation of ulcerative colitisThe study of the treatment and rehabilitation of ulcerative colitis Ulcerative Colitis1:5-ASA and low residue diet;2:5-ASA and EN;3:5-ASA and low residue diet and microecology prepar;4:5-ASA and low residue diet ang Gln;5:5-ASA and EN and Gln and microecology preparation;Friendship Hospital of Capital Medical UniversityNULLCompleted1870Both1:60;2:60;3:60;4:60;5:60;I (Phase 1 study)China
62NCT00621257
(ClinicalTrials.gov)
January 200811/2/2008Vitamin D Levels in Children With IBDOptimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.Inflammatory Bowel Disease;Crohn's Disease;Ulcerative ColitisDietary Supplement: ergocalciferol;Dietary Supplement: CholecalciferolBoston Children’s HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Crohn's and Colitis Foundation;NASPGHAN FoundationTerminated5 Years21 YearsAll134N/AUnited States
63NCT00578799
(ClinicalTrials.gov)
December 200718/12/2007Effects of Probiotics in Patients With Ulcerative ColitisEffects of Probiotics in Patients With Ulcerative Colitis.Ulcerative ColitisDietary Supplement: Kyo-Dophilus;Dietary Supplement: placeboUniversity of California, IrvineWakunaga Pharmaceutical Co., Ltd.Withdrawn18 Years65 YearsAll0Phase 1United States
64NCT02093767
(ClinicalTrials.gov)
August 200719/3/2014Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative ColitisOpen-Label Trial of a Prebiotic Preparation Containing Inulin and Oligofructose (Synergy-1) for the Treatment of Mild to Moderate Acute Ulcerative ColitisUlcerative ColitisDietary Supplement: Synergy1University of AlbertaCanadian Institutes of Health Research (CIHR);Crohn's and Colitis Canada;Beneo GmbHCompleted18 Years65 YearsAll24N/ACanada
65NCT00403923
(ClinicalTrials.gov)
April 200724/11/2006Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative ColitisA Study to Determine the Threshold of Lactose Ingestion That Provokes Symptoms in Lactose Intolerant People Who Also Have Ulcerative ColitisLactose Intolerance;Ulcerative ColitisDietary Supplement: Lactose in waterUniversity Hospitals, LeicesterNULLCompleted18 YearsN/ABoth48United Kingdom
66NCT00951548
(ClinicalTrials.gov)
October 20062/8/2009Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative ColitisFood Supplementation With the Probiotic Preparation VSL#3 as a Support to Standard Pharmaceutical Therapy in Patients With Mild to Moderate Active Ulcerative Colitis. A Double-blind, Randomized, Placebo Controlled StudyUlcerative ColitisDietary Supplement: VSL#3;Dietary Supplement: PlaceboVSL PharmaceuticalsNULLCompleted18 YearsN/ABoth144N/AItaly
67EUCTR2004-000611-25-IE
(EUCTR)
19/10/200416/08/2004A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - COREA Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - CORE Maintenance of remission of ulcerative colitisProduct Name: OPC-6535
Product Code: OPC-6535
Other descriptive name: 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid
Trade Name: Asacol (mesalamine) Delayed-release Tablets
Product Name: Asacol
INN or Proposed INN: Mesalamine
Other descriptive name: 5-amino-2-hydroxybenzoic acid
Otsuka Maryland Research Institute, Inc.NULLNot RecruitingFemale: yes
Male: yes
1725Phase 3Hungary;Ireland
68EUCTR2004-000611-25-HU
(EUCTR)
15/10/200421/07/2004A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - COREA Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. - CORE Maintenance of remission of ulcerative colitisProduct Name: OPC-6535
Product Code: OPC-6535
Other descriptive name: 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid
Trade Name: Asacol (mesalamine) Delayed-release Tablets
Product Name: Asacol
INN or Proposed INN: Mesalamine
Other descriptive name: 5-amino-2-hydroxybenzoic acid
Otsuka Maryland Research Institute, Inc.NULLNot RecruitingFemale: yes
Male: yes
1725Phase 3Hungary;Ireland
69NCT00259558
(ClinicalTrials.gov)
April 200325/11/2005Dose Finding Study for Retarded Phosphatidylcholine in PancolitisProspektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis UlcerosaUlcerative ColitisDrug: retarded release phosphatidylcholineHeidelberg UniversityProf. Wolfgang Stremmel;Dietmar Hopp StiftungCompleted16 Years90 YearsBoth60Phase 2Germany
70NCT00259571
(ClinicalTrials.gov)
April 200328/11/2005Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.Prospektive, Randomisierte, Doppelblinde, Mesalazin-kontrollierte (Double-dummy Verfahren) Multizenter-Studie Zur Beurteilung Der Annahme Der äquivalenten Wirkung Von Intestinal Retardiert Freigesetztem Phosphatidylcholin gegenüber Mesalazin (Non-inferiority Study) in Der Remissionserhaltung Der Colitis Ulcerosa.Ulcerative ColitisDrug: retarded release phosphatidylcholineHeidelberg UniversityDietmar Hopp StiftungWithdrawn15 Years80 YearsBoth0Phase 2/Phase 3Germany
71NCT00259545
(ClinicalTrials.gov)
February 200325/11/2005Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative ColitisProspektive, Randomisierte Doppelblinde Studie Zur Wirksamkeit Von Intestinal Retardiert Freigesetztem Phosphatidylcholine Bei therapierefraktärer Colitis Ulcerosa Mit Chronisch Aktivem Verlauf Unter CorticosteroidenUlcerative Colitis;PhosphatidylcholineDrug: Retarded Release Phosphatidylcholine (rPC)Heidelberg UniversityProfessor Wolfgang Stremmel;Dietmar Hopp StiftungCompleted16 Years90 YearsBoth60Phase 2Germany
72NCT00940576
(ClinicalTrials.gov)
July 200015/7/2009Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel DiseasesDietetic Effects of Mare's Milk in Patients With Chronic Inflammatory Bowel Diseases (IBD) - a Double Blind Placebo Controlled Cross-over Study.Ulcerative Colitis;Crohns DiseaseDietary Supplement: mare´s milk;Other: placebo drinkUniversity of JenaGerman Federal Ministry of Education and ResearchCompleted10 Years50 YearsAll17N/AGermany

240. フェニルケトン尿症


臨床試験数 : 143 薬物数 : 90 - (DrugBank : 10) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04272736
(ClinicalTrials.gov)
December 1, 202229/8/2018PKU Low Calorie Drink StudyEvaluating the Compliance, Acceptability, Safety and Tolerance of a Lower Calorie Protein Substitute for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot StudyPhenylketonurias;HyperphenylalaninaemiaDietary Supplement: Low calorie protein substituteNutricia UK LtdNULLNot yet recruiting3 YearsN/AAll30N/ANULL
2NCT05270837
(ClinicalTrials.gov)
June 17, 20221/2/2022Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With PhenylketonuriaA Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) With Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs Diet-Only Control) DesignPhenylketonuria (PKU)Drug: Pegvaliase;Other: Diet OnlyBioMarin PharmaceuticalNULLRecruiting12 Years17 YearsAll54Phase 3United States;Germany
3NCT04898829
(ClinicalTrials.gov)
May 18, 202211/5/2021Evaluation of PKU Explore FranceAn Exploratory Study to Evaluate the Acceptability of PKU Explore, a Food for Special Medical Purposes, for Use in the Dietary Management of Phenylketonuria in Infants From 6 Months to 3 Years of Age With Regard to Product-acceptability, Tolerance, Phe Levels and GrowthPhenylketonuriasDietary Supplement: PKU exploreVitaflo International, LtdNULLRecruiting6 Months3 YearsAll10N/AFrance
4NCT05096988
(ClinicalTrials.gov)
November 23, 202114/10/2021Evaluation of PKU Sphere LiquidA Study to Evaluate the Acceptability, Tolerance and Adherence of Children and Adults Consuming PKU Sphere Liquid, a Food for Special Medical Purposes (FSMP), for the Dietary Management of Phenylketonuria (PKU)PhenylketonuriasDietary Supplement: PKU sphere liquidVitaflo International, LtdNULLActive, not recruiting3 YearsN/AAll19N/AUnited Kingdom
5NCT05051657
(ClinicalTrials.gov)
June 14, 202110/9/2021Evaluation of PKU Express PlusA Study To Evaluate The Acceptability Of PKU Express Plus, A Food For Special Medical Purposes (FSMP), In Children And Adults With Phenylketonuria (PKU)Phenylketonurias;PKUDietary Supplement: PKU express plusVitaflo International, LtdNULLRecruiting3 YearsN/AAll15N/AUnited Kingdom
6NCT04375592
(ClinicalTrials.gov)
February 1, 202121/4/2020Acceptability and Tolerance of a Ready-to-use Protein Substitute in Tablet Form for the Dietary Management of PhenylketonuriaXPhe Minis - Acceptability and Tolerance Market ResearchPhenylketonurias;Hyperphenylalaninaemia;Tetrahydrobiopterin DeficiencyDietary Supplement: Phenylalanine-free protein substitute in tablet form (XPhe minis)metaX Institut fuer Diatetik GmbHBirmingham Children's HospitalRecruiting7 Years18 YearsAll10United Kingdom
7NCT05062226
(ClinicalTrials.gov)
September 16, 20206/9/2021GMP Case Studies of Tolerance, Safety and Acceptability in PKU and TYREvaluating the Tolerance, Safety and Acceptability of GMP-based Protein Substitutes for the Dietary Management of Phenylketonuria and Tyrosinaemia in Children and Adults: a Case Study SeriesPKU;TyrosinemiasDietary Supplement: PKU/TYR GMP Protein SubstituteNutricia UK LtdNULLRecruiting3 YearsN/AAll45N/AUnited Kingdom
8NCT04302194
(ClinicalTrials.gov)
May 1, 20207/3/2020Early Dietary Treated Patients With Phenylketonuria Can Achieve Normal Growth and Mental Development.Early Dietary Treated Patients With Phenylketonuria Can Achieve Normal Growth and Mental Development.PhenylketonuriasDietary Supplement: phenylalanine restricted dietAssiut UniversityNULLNot yet recruiting1 Month3 YearsAll50NULL
9NCT04679467
(ClinicalTrials.gov)
January 15, 202026/11/2020Evaluation of PKU Sphere in ItalyAn Acceptability Study to Evaluate the Tolerance, Adherence and Metabolic Control of Patients With Phenylketonuria (PKU) Consuming PKU Sphere™, a Glycomacropeptide (GMP) Based Protein Substitute, When Introduced According to a Practical Guide to PKU Sphere.Phenylketonurias;PKUDietary Supplement: PKU sphereVitaflo International, LtdNULLCompleted3 YearsN/AAll13N/AItaly
10NCT04404530
(ClinicalTrials.gov)
October 8, 201921/5/2020Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)Palynziq and PKU: Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status, and the MetabolomePhenylketonuriasDrug: PalynziqEmory UniversityBioMarin PharmaceuticalRecruiting16 YearsN/AAll45United States
11NCT03924180
(ClinicalTrials.gov)
September 19, 201922/4/2019Glytactin EfficiEncy in Non or Insufficiently Treated Adult PHENylketonuria PatientsGlytactin EfficiEncy in Non or Insufficiently Treated Adult PHENylketonuria PatientsAdult Phenylketonuria Non Treated PatientsDietary Supplement: Dietary Supplement for PKU patientsUniversity Hospital, ToursNULLCompleted18 YearsN/AAll13N/AFrance
12NCT03788343
(ClinicalTrials.gov)
August 19, 201917/12/2018Phenylalanine and Its Impact on CognitionPICO: Phenylalanine and Its Impact on Cognition - Impact of Phenylalanine on Cognitive, Cerebral and Neurometabolic Parameters in Adult Patients With PhenylketonuriaPhenylketonuriaDietary Supplement: Phenylalanine;Drug: PlaceboUniversity Hospital Inselspital, BerneUniversity of ZurichCompleted18 YearsN/AAll90Phase 4Switzerland
13NCT04224142
(ClinicalTrials.gov)
July 29, 20197/10/2019Evaluation of PKU Sphere in Maternal PKUAn Observational Study to Evaluate Metabolic Control and Dietary Management in Women With PKU Taking PKU Sphere During Pre-conception and/or PregnancyMaternal PhenylketonuriaDietary Supplement: PKU sphereVitaflo International, LtdUniversity College London HospitalsRecruiting16 YearsN/AFemale10United Kingdom
14NCT03939052
(ClinicalTrials.gov)
July 19, 20191/5/2019Protein Requirements in Adults With Phenylketonuria (PKU)Protein Requirements in Phenylketonuria (PKU) Patients Compared Using PKU Sphere™ | Glycomacropeptide (GMP) and an L-amino Acid-based ProductPhenylketonuriaDietary Supplement: Free amino acids intakeUniversity of British ColumbiaVitaflo International, LtdRecruiting19 Years50 YearsAll6N/ACanada
15NCT03333720
(ClinicalTrials.gov)
July 15, 201918/9/2017Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of PhenylketonuriaCompliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of PhenylketonuriaPhenylketonuriasDietary Supplement: Phenylalanine-free protein substitute tabletsNutricia UK LtdNULLWithdrawn8 Years100 YearsAll0N/ANULL
16NCT03820804
(ClinicalTrials.gov)
January 7, 201919/10/2018Nutritional Status in PhenylketonuriaTrends in Nutritional Status of Patients With PhenylketonuriaPhenylketonuriasOther: Diet;Drug: SapropterinUniversidade do PortoCentro Hospitalar do Porto;BioMarin PharmaceuticalCompleted3 YearsN/AAll94Portugal
17NCT03771391
(ClinicalTrials.gov)
December 6, 20187/12/2018A 16 Week Study Evaluating the Introduction of a GMP Based Protein Substitute in Participants With PKUMulticentre Study Project to Evaluate the New Generation of Protein Supplements With Glycomacropeptide (GMP) in Patients With Phenylketonuria (PKU) Aged 10 Years and Older Over a 16 Week Period.PhenylketonuriasDietary Supplement: PKU SphereVitaflo International, LtdKreiskliniken Reutlingen;Johannes Gutenberg University MainzActive, not recruiting10 YearsN/AAll15N/AGermany
18NCT03419819
(ClinicalTrials.gov)
May 1, 20183/1/2018Evaluation of PKU SphereEvaluation of the Acceptability, Tolerance, and Satiety of PKU Sphere, a Glycomacropeptide (GMP) Based Medical Food in Patients With Phenylketonuria (PKU).PhenylketonuriasDietary Supplement: PKU SphereVitaflo International, LtdOregon Health and Science UniversityCompleted3 YearsN/AAll28N/AUnited States
19NCT02677870
(ClinicalTrials.gov)
January 22, 201826/1/2016The Effectiveness of Kuvan in Amish PKU PatientsThe Effectiveness of High-Dose Synthetic BH4 (Saproterin Dihydrochloride or Kuvan) in Amish PKU PatientsPhenylketonuriaDrug: saproterin dihydrochloride;Other: Diet treatmentUniversity Hospitals Cleveland Medical CenterBioMarin PharmaceuticalCompleted2 Years60 YearsAll7Phase 4United States
20NCT03168399
(ClinicalTrials.gov)
June 8, 201724/5/2017Evaluation of PKU ExploreA Study to Evaluate the Acceptability of PKU Explore, a Renovated Phenylalanine Free Second Stage Protein Substitute for Use in the Dietary Management of Phenylketonuria in Infants From 6 Months to 5 Years of Age With Regard to Product Tolerance and Adherence.Phenylketonuria;Inborn Errors of MetabolismDietary Supplement: PKU ExploreVitaflo International, LtdBirmingham Women's and Children's NHS Foundation TrustCompleted6 Months5 YearsAll22N/AUnited Kingdom
21NCT03167697
(ClinicalTrials.gov)
May 1, 201722/5/2017Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or HyperphenylalaninemiaEvaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or HyperphenylalaninemiaPhenylketonurias;Hyperphenylalaninaemia, Type IDietary Supplement: Synergy;Other: RoutineNutricia UK LtdNULLCompleted16 Years100 YearsAll14N/AUnited Kingdom
22NCT03058848
(ClinicalTrials.gov)
March 6, 201716/2/2017Evaluation of PKU StartA Study to Evaluate the Acceptability of a New Phenylalanine Free Infant Formula for Use in the Dietary Management of Phenylketonuria in Infants From Birth to 2 Year of Age With Regard to Product Tolerance and Adherence.Phenylketonuria;Inborn Errors of MetabolismDietary Supplement: PKU StartVitaflo International, LtdNULLCompletedN/A2 YearsAll10N/AUnited Kingdom
23NCT02915510
(ClinicalTrials.gov)
July 20168/8/2016GMP Drink for PKU StudyEvaluating the Tolerance, Safety and Acceptability of PKU GMPro, a Whey Protein Derived Feed for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot TrialPhenylketonuriaDietary Supplement: Glycomacropeptide-based protein substituteNutricia UK LtdNULLCompleted3 YearsN/AAll40N/AUnited Kingdom
24NCT02440932
(ClinicalTrials.gov)
November 201430/4/2015Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced ThermogenesisImpact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced ThermogenesisPhenylketonuria (PKU)Dietary Supplement: Phenylketonuria-type diet;Other: Normal (control) dietUniversity of GlasgowNULLCompleted18 Years45 YearsBoth26N/AUnited Kingdom
25EUCTR2010-021343-41-NL
(EUCTR)
21/03/201430/11/2011Variations of blood phenylalanine and tyrosine in children with phenylketonuria under sapropterinEffect of sapropterin on variations of blood phenylalanine and tyrosine over 24 hours and from day to day in children with phenylketonuria Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder by a mutation in the gene for the enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. Left untreated, the disease will result in high concentrations of phenylalanine (Phe) in blood and tissues, likely resulting in severe mental retardation and behavioural problems. Treatment focusus on the restriction of dietary phenylalanine intake with supplementation of a synthetic phenylalaninefree amino acid mixture.;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Trade Name: KuvanUniversity Medical Center GroningenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 4Netherlands
26NCT01965691
(ClinicalTrials.gov)
October 201316/10/2013Protein Requirements in Children With Phenylketonuria (PKU)Application of Stable Isotopes to Determine Protein Requirements in Children With Phenylketonuria (PKU)PhenylketonuriaDietary Supplement: Protein intakeUniversity of British ColumbiaRare Disease Foundation, Vancouver, Canada;Saudi Arabian Cultural Bureau, OttawaCompleted5 Years18 YearsAll4N/ACanada
27NCT01617070
(ClinicalTrials.gov)
May 20128/6/2012Effects of Kuvan on Melatonin SecretionPilot Study to Evaluate Melatonin Secretion as a Marker of Decreased Serotonin in Individuals With PKU: Evaluation of the CNS Effects of TetrahydrobiopterinPhenylketonuria (PKU)Drug: Kuvan;Dietary Supplement: Large Neutral Amino Acid TherapyUniversity of Southern CaliforniaBioMarin PharmaceuticalCompleted18 YearsN/AAll10Phase 4United States
28NCT01376908
(ClinicalTrials.gov)
June 201117/6/2011Kuvan® in Phenylketonuria Patients Less Than 4 Years OldA Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patients <4 Years Old.PhenylketonuriaDrug: Kuvan®;Other: Phenylalanine (Phe)-restricted dietBioMarin PharmaceuticalNULLCompletedN/A4 YearsAll56Phase 3Austria;Belgium;Czechia;Germany;Italy;Netherlands;Slovakia;Turkey;United Kingdom;Czech Republic;Portugal
29NCT01412437
(ClinicalTrials.gov)
April 20111/8/2011Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in PhenylketonuriaMultimodal Neuroimaging and Neurocognitive Assessment of Biomarkers and Response to Sapropterin Dihydrochloride Treatment in PhenylketonuriaPKUDietary Supplement: diet;Drug: sapropterin dihydrochlorideChildren's Research InstituteGeorgetown UniversityWithdrawn18 Years40 YearsBoth0N/AUnited States
30NCT00841100
(ClinicalTrials.gov)
December 200810/2/2009Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan ResponseKuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan ResponsePhenylketonuriaDrug: Kuvan;Other: DietUniversity of MiamiNULLCompleted4 YearsN/AAll21Phase 2United States
31NCT00892554
(ClinicalTrials.gov)
June 20071/5/2009The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)The Impact of Docosahexaenoic Acid on Neuropsychological Status in Females With PhenylketonuriaPhenylketonuriaDietary Supplement: Docosahexaenoic Acid;Dietary Supplement: Corn/soy oilEmory UniversityAtlanta Clinical and Translational Science InstituteCompleted12 Years50 YearsFemale33N/AUnited States
32EUCTR2005-003777-24-GB
(EUCTR)
17/08/200620/04/2006A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NAA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NA Phenylketonuria (PKU)
MedDRA version: 6.1;Classification code 10034872
Product Name: Phenoptin
Product Code: T1401
INN or Proposed INN: Sapropterin
Other descriptive name: sapropterin dihydrochloride
BioMarin Pharmaceutical Inc.NULLNot Recruiting Female: yes
Male: yes
300 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noSpain;Germany;United Kingdom
33EUCTR2005-003777-24-DE
(EUCTR)
24/03/200614/12/2005A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NAA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet - NA Phenylketonuria (PKU)
MedDRA version: 6.1;Classification code 10034872
Product Name: Phenoptin
Product Code: T1401
INN or Proposed INN: Sapropterin
Other descriptive name: sapropterin dihydrochloride
BioMarin Pharmaceutical Inc.NULLNot RecruitingFemale: yes
Male: yes
300Phase 3Germany;Spain
34EUCTR2005-003777-24-ES
(EUCTR)
01/03/200619/01/2006Estudio fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de PhenoptinTM en dosis de 20 mg/kg/dia para aumentar la tolerancia a la fenilalanina en niños fenilcetonúricos que siguen dietas restrictivas en fenilalanina.Estudio fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de PhenoptinTM en dosis de 20 mg/kg/dia para aumentar la tolerancia a la fenilalanina en niños fenilcetonúricos que siguen dietas restrictivas en fenilalanina. Fenilcetonuria (Phenylketonuria-PKU)
MedDRA version: 6.1;Classification code 10034872
Product Name: Phenoptin
Product Code: T1401
INN or Proposed INN: Sapropterin
Other descriptive name: Sapropterin dihydrochloride
BioMarin Pharmaceutical Inc.NULLNot RecruitingFemale: yes
Male: yes
300Phase 3Spain;Germany;United Kingdom
35EUCTR2004-002365-21-DK
(EUCTR)
03/11/200409/07/2008Trial with BH4, a new and simple treatment of phenylketonuria, PKU - BH4 and PKUTrial with BH4, a new and simple treatment of phenylketonuria, PKU - BH4 and PKU PKU, phenylketonuria, is a rare, inherited metabolic disease that results in mental retardation if not a very strict low-protein diet is started within the first weeks of life. The conversion of phenylalanine to tyrosine is defect, phe accumulates and leads to brain damage. There are different degrees of severity, reflecting the spectrum of mutant genes. BH4, tetrahydrobiopterin, is co-enzym for the conversion of phe to tyrosine. BH4 can lower phe in some patients with milder forms of PKU.Product Name: tetrahydrobiopterinJohn F. Kennedy InstituteNULLNot RecruitingFemale: yes
Male: yes
Denmark

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05523180
(ClinicalTrials.gov)
September 1, 202222/8/2022A Study to Evaluate the Effect of Probiotic Supplement on Quality of LifeA Prospective, Randomized, Double-blinded, Placebo-controlled Study Evaluating the Safety and Impact of resB® Lung Support on Quality of Life in Adult Volunteers With Chronic Obstructive Pulmonary Disease or Non-cystic Fibrosis BronchiectasisChronic Obstructive Pulmonary Disease;Non-cystic Fibrosis BronchiectasisDietary Supplement: Probiotic;Other: PlaceboResBiotic Nutrition, Inc.Nutrasource Pharmaceutical and Nutraceutical Services, Inc.Recruiting18 Years80 YearsAll50N/AUnited States
2NCT03931252
(ClinicalTrials.gov)
January 202225/4/2019Thermic Effect of Feeding in Cystic FibrosisThermic Effect of Feeding in Cystic FibrosisCystic FibrosisDietary Supplement: Boost VHC;Dietary Supplement: Ensure High ProteinVirginia Commonwealth UniversityNULLEnrolling by invitation18 YearsN/AAll10N/AUnited States
3NCT04938726
(ClinicalTrials.gov)
November 1, 20219/6/2021Ketone Supplementation in Cystic FibrosisKetone Monoester Supplementation in Cystic Fibrosis: A Pilot and Feasibility StudyCystic FibrosisDietary Supplement: Ketone MonoesterUniversity of Alabama at BirminghamNULLRecruiting18 Years89 YearsAll25N/AUnited States
4NCT04531410
(ClinicalTrials.gov)
July 1, 202118/8/2020NETwork of Linoleic Acid Supplementation in Cystic FibrosisDouble-blind Randomized Controlled Study of Linoleic Acid Supplementation for 1 Year in Patients With Cystic Fibrosis - Influence on Clinical Status and MetabolismCystic FibrosisDietary Supplement: linoleic acid supplementation;Dietary Supplement: oleic acid supplementationKarolinska InstitutetEuropean Society of Pediatric Gastroenterology, Hepatology and NutritionEnrolling by invitation5 Years15 YearsAll90N/AItaly;Norway;Poland;Sweden
5NCT04496921
(ClinicalTrials.gov)
August 10, 202021/7/2020Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic FibrosisVitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis : A Pilot StudyCystic FibrosisDietary Supplement: Vitamin K supplementation, dose #1;Dietary Supplement: Vitamin K supplementation, dose #2Institut de Recherches Cliniques de MontrealUniversité de MontréalWithdrawn18 YearsN/AAll0N/ACanada
6NCT04058340
(ClinicalTrials.gov)
July 30, 201912/8/2019Taste Receptors Regulation in CF PatientsThe Effects of Taste Receptors Regulation in Upper Airway Innate Immunity of CF PatientsCystic FibrosisDietary Supplement: lactizole nebulization;Other: PlaceboMedical Universtity of LodzNULLRecruiting6 YearsN/AAll30N/APoland
7NCT03734744
(ClinicalTrials.gov)
June 17, 20196/11/2018PK/PD of Vitamin D3 in Adults With CFA Pilot Study Evaluating Single, High-dose Pharmacokinetics/Pharmacodynamics of Vitamin D3 in CFVitamin D Deficiency;Cystic FibrosisDietary Supplement: Vitamin D3University of Southern CaliforniaNULLTerminated18 YearsN/AAll6N/AUnited States
8NCT04966897
(ClinicalTrials.gov)
August 31, 20188/7/2021Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic FibrosisRandomized, Double-blind, Cross-over Trial Assessing a PERT-free Nutritional Therapeutic Delivery System for Cystic FibrosisCystic Fibrosis;Exocrine Pancreatic InsufficiencyDietary Supplement: GlycosBio Nutritional Supplement + PERT placebo;Dietary Supplement: Standard Nutritional Supplement + PERTGlycosBio, Inc.Baylor College of MedicineCompleted12 YearsN/AAll10N/AUnited States
9NCT03462056
(ClinicalTrials.gov)
May 17, 20185/3/2018Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic FibrosisPilot Study of Ready to Use Therapeutic Food to Promote Weight Gain in Cystic FibrosisCystic FibrosisDietary Supplement: Cystic Fibrosis Ready to Use Supplemental FoodWashington University School of MedicineCystic Fibrosis FoundationCompleted2 Years12 YearsAll16Phase 1/Phase 2United States
10NCT03205904
(ClinicalTrials.gov)
December 12, 201615/6/2017Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.Cystic Fibrosis-related Diabetes;Cystic FibrosisDietary Supplement: DietHospital de Clinicas de Porto AlegreNULLCompleted10 YearsN/AAll20N/ABrazil
11NCT02810691
(ClinicalTrials.gov)
July 201614/6/2016The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic FibrosisThe Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic FibrosisCystic Fibrosis-related Diabetes;Cystic FibrosisDietary Supplement: Soluble fiber supplementation;Dietary Supplement: Placebo (for fiber supplementation)Institut de Recherches Cliniques de MontrealCanadian Cystic Fibrosis Foundation;Université de MontréalCompleted18 YearsN/AAll14N/ACanada
12NCT02646995
(ClinicalTrials.gov)
January 201622/12/2015Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) PatientsCystic FibrosisDietary Supplement: modified lipid formulation;Dietary Supplement: Fish oilNestléNULLCompleted5 Years18 YearsAll16N/ASwitzerland
13NCT02589444
(ClinicalTrials.gov)
December 201520/10/2015Vitamin D and Microbiota in Cystic FibrosisPilot Study Evaluating the Role of Vitamin D Repletion on Gut and Lung Microbiota in Cystic FibrosisVitamin D Deficiency;Cystic FibrosisDietary Supplement: High-Dose Vitamin D3;Other: Stool Sample;Other: Sputum Sample;Other: Sham Comparator;Procedure: Blood drawEmory UniversityNULLCompleted18 YearsN/AAll41N/AUnited States
14NCT02518672
(ClinicalTrials.gov)
October 20153/8/2015Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.Cystic FibrosisDietary Supplement: MAG-DHA;Dietary Supplement: PlaceboSCF PharmaCentre de recherche du Centre hospitalier universitaire de Sherbrooke;Solutex (Spain)Terminated18 YearsN/AAll11Phase 2Canada
15NCT02043717
(ClinicalTrials.gov)
January 201412/1/2014Increased Vitamin D Reduces Pulmonary Exacerbations in CFIncreasing Vitamin D Serum Levels Reduces Pulmonary Exacerbations in Patients With Cystic FibrosisCystic FibrosisDietary Supplement: Vitamin DHadassah Medical OrganizationNULLCompleted4 YearsN/AAll90N/AIsrael
16NCT00924547
(ClinicalTrials.gov)
November 201317/6/2009Oral Docosahexanoic Acid Supplementation in Cystic FibrosisOral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in PlasmaCystic FibrosisDietary Supplement: Docosahexanoic Acid Supplement;Dietary Supplement: PlaceboVanderbilt UniversityNULLCompleted6 YearsN/ABoth17Phase 2United States
17NCT01880346
(ClinicalTrials.gov)
October 201312/6/2013Comparison of Absorption of Vitamin D in Cystic FibrosisVehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs OilCystic FibrosisDietary Supplement: Vitamin D Powder;Dietary Supplement: Vitamin D OilEmory UniversityNULLCompleted18 Years59 YearsBoth17Phase 4United States
18NCT02048592
(ClinicalTrials.gov)
September 201316/12/2013Impact of Immunonutrition on the Patients With Cystic FibrosisImpact of Immunonutrition on the Patients With Cystic FibrosisCystic Fibrosis;Malnutrition;Oxidative StressDietary Supplement: Impact-Nutridrink;Dietary Supplement: Nutridrink-ImpactUniversity Hospital, MotolNULLRecruiting18 Years40 YearsBoth30Phase 4Czech Republic
19NCT01859390
(ClinicalTrials.gov)
June 201317/5/2013Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic FibrosisA Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis PatientsCystic FibrosisDrug: AquADEKs-2;Dietary Supplement: control multivitaminUniversity of Colorado, DenverCystic Fibrosis Foundation Therapeutics;Yasoo HealthCompleted10 YearsN/AAll73Phase 2United States
20NCT01837355
(ClinicalTrials.gov)
March 201310/4/2013Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic FibrosisModulation of Intestinal and Pulmonary Inflammation by Lactobacillus Rhamnosus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)Pulmonary Inflammation;Cystic Fibrosis;MicrobiotaDietary Supplement: Lactobacillus rhamnosus;Dietary Supplement: PlaceboCantonal Hospital of St. GallenSwiss Federal Institute of Technology;University Hospital Inselspital, BerneUnknown status6 Years20 YearsAll68N/ASwitzerland
21NCT02014181
(ClinicalTrials.gov)
July 201227/11/2013Flaxseed Modulates Inflammation and Oxidative Stress in CFFlaxseed Modulates Oxidative Stress and Inflammatory Biomarkers in Stable Patients With Cystic Fibrosis and Healthy ControlsCystic Fibrosis;Oxidative Stress;InflammationDietary Supplement: finely ground flaxseed powderUniversity of PennsylvaniaNULLCompleted18 Years64 YearsBoth10Phase 1United States
22NCT01417481
(ClinicalTrials.gov)
March 201215/8/2011Effect of Glycine in Cystic FibrosisEvaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic FibrosisCystic FibrosisDietary Supplement: Glycine;Dietary Supplement: PlaceboInstituto Nacional de Enfermedades RespiratoriasHospital Infantil de Mexico Federico Gomez;Instituto Mexicano del Seguro SocialTerminated5 Years15 YearsAll13Phase 2Mexico
23NCT02128984
(ClinicalTrials.gov)
January 201228/3/2014Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished ChildrenClinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished ChildrenCystic Fibrosis;Failure to Thrive;MalnutritionDietary Supplement: Symbiotic Formula with DHA and antioxidants;Dietary Supplement: Standard FormulaLaboratorios OrdesaQuantum Experimental;Peruvian Clinical ResearchCompleted1 YearN/AAll109N/APeru;Spain
24NCT00889434
(ClinicalTrials.gov)
November 1, 201120/4/2009Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CFCystic FibrosisDietary Supplement: ECGC;Dietary Supplement: Tocotrienol;Dietary Supplement: EGCG + TocotrienolHadassah Medical OrganizationNULLCompleted18 YearsN/AAll7N/AIsrael
25NCT01426256
(ClinicalTrials.gov)
October 201129/8/2011Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)Vitamin D for Enhancing the Immune System in Cystic FibrosisCystic Fibrosis;Respiratory Tract InfectionsDietary Supplement: CholecalciferolEmory UniversityCystic Fibrosis Foundation TherapeuticsCompleted16 YearsN/AAll91Phase 3United States
26NCT01783613
(ClinicalTrials.gov)
October 201131/1/2013Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic FibrosisStudy of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic FibrosisCystic FibrosisDietary Supplement: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months;Dietary Supplement: Placebo: 50 mg/kg/day during 12 monthsFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNULLCompleted2 Months100 YearsAll96N/ASpain
27NCT01772758
(ClinicalTrials.gov)
August 201116/10/2012Cystic Fibrosis and Endothelial Function: At Rest and During ExerciseInfluence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During ExerciseCystic FibrosisDrug: BH4 5mg;Drug: BH4 20mg;Dietary Supplement: Antioxidant CocktailAugusta UniversityNULLCompleted7 YearsN/AAll64Phase 2United States
28NCT01315665
(ClinicalTrials.gov)
April 201114/3/2011Effect of Sulforaphane in Broccoli Sprouts on Nrf2 ActivationEvaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF SubjectsCystic FibrosisDietary Supplement: Broccoli sproutsUniversity Hospitals Cleveland Medical CenterCystic Fibrosis FoundationCompleted18 Years49 YearsAll15N/AUnited States
29NCT02029521
(ClinicalTrials.gov)
March 201130/12/2013Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis PatientsSupplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth FailureCystic FibrosisDietary Supplement: Oral reduced l-glutathione;Dietary Supplement: PlaceboClark BishopNULLCompleted18 Months10 YearsAll47N/AItaly
30NCT01494909
(ClinicalTrials.gov)
January 201115/12/2011Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and FunctionDevelopment Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and FunctionCystic FibrosisDietary Supplement: Ensure plusTexas A&M UniversityArkansas Children's Hospital Research Institute;University of ArkansasActive, not recruiting10 YearsN/AAll31N/AUnited States
31NCT01956916
(ClinicalTrials.gov)
October 201023/9/2013Probiotics in Cystic FibrosisEffects of LGG Administration in Children With Cystic Fibrosis: A Randomized Controlled TrialCystic FibrosisDietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placeboFederico II UniversityNULLCompleted2 Years18 YearsBoth110Phase 3Italy
32NCT01201434
(ClinicalTrials.gov)
October 201031/8/2010Effect of Probiotics on Sputum Inflammation and Pulmonary Infections in Patients With Cystic FibrosisThe Effect of Probiotics on Sputum Bacteria, Sputum Inflammation, and Pulmonary Infections in Patients With Cystic Fibrosis: A Double-blind Placebo-controlled TrialCystic FibrosisDietary Supplement: Bio-25 probioticSheba Medical CenterNULLTerminated5 Years40 YearsBoth12N/ANULL
33NCT01222273
(ClinicalTrials.gov)
September 201014/10/2010Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary AspergillosisOpen-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary AspergillosisCystic Fibrosis;Allergic Bronchopulmonary AspergillosisDietary Supplement: cholecalciferol (Vitamin D3)University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)Completed12 YearsN/AAll7N/AUnited States
34NCT01321905
(ClinicalTrials.gov)
April 201023/3/2011Prospective Intervention Study on Vitamin D in Patients With Cystic Fibrosis5-month Pilot Intervention Study on Vitamin D in Patients With Cystic FibrosisCystic FibrosisDietary Supplement: Supplementation with vitamin D2/D3Karolinska InstitutetStockholm County Council, Sweden;Swedish Cystic Fibrosis AssociationRecruiting6 YearsN/ABoth15Phase 2Sweden
35NCT01051999
(ClinicalTrials.gov)
February 201015/1/2010Glutamine Supplementation in Cystic FibrosisGlutamine Supplementation and Immunity in Adults With Cystic FibrosisCystic Fibrosis;Immune FunctionDietary Supplement: Glutamine;Dietary Supplement: L-alanineEmory UniversityEmmaus Medical, Inc.Completed18 YearsN/ABoth17Phase 2United States
36NCT01961661
(ClinicalTrials.gov)
September 20099/10/2013Probiotics on Intestinal Inflammation in Cystic FibrosisEffect of Probiotics on Intestinal Inflammation and Microflora in Cystic Fibrosis: a Pilot StudyCystic FibrosisDietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placeboFederico II UniversityNULLCompleted2 Years18 YearsBoth22Phase 3Italy
37NCT01737983
(ClinicalTrials.gov)
May 200912/7/2012Effect of Lactobacillus Reuteri in Cystic FibrosisLactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.CYSTIC FIBROSISDietary Supplement: Lactobacillus reuteri;Dietary Supplement: placeboAzienda Policlinico Umberto INULLCompleted6 Years42 YearsBoth61Phase 4Italy
38NCT00685971
(ClinicalTrials.gov)
December 200827/5/2008Cholecalciferol for Vitamin D in Adult Cystic Fibrosis (CF) PatientsRandomized Placebo-Controlled Trial of Cholecalciferol for Vitamin D Deficiency in Adults With Cystic FibrosisCystic Fibrosis;Vitamin D DeficiencyDietary Supplement: 5000 IU of cholecalciferol;Dietary Supplement: placeboSt. Michael's Hospital, TorontoNULLCompleted18 YearsN/ABoth200N/ACanada
39NCT00788138
(ClinicalTrials.gov)
October 20087/11/2008Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic FibrosisCystic FibrosisDietary Supplement: Vitamin D3;Dietary Supplement: PlaceboEmory UniversityNULLCompleted18 Years70 YearsBoth30N/AUnited States
40NCT00959010
(ClinicalTrials.gov)
October 200813/8/2009Omega 3 Supplementation in Cystic Fibrosis PatientsBiochemical Effects of a Long-term Supplementation With Omega-3 Polyunsaturated Fatty Acids in Cystic FibrosisCystic FibrosisDietary Supplement: omega-3 triglycerides;Dietary Supplement: PlaceboQueen Fabiola Children's University HospitalNULLCompleted6 Years60 YearsBoth15Phase 3Belgium
41NCT01172301
(ClinicalTrials.gov)
July 200827/7/2010Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic FibrosisLeucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic FibrosisCystic FibrosisDietary Supplement: Essential amino acid intake + Leucine vs total AA supplementTexas A&M UniversityArkansas Children's Hospital Research InstituteCompleted10 Years21 YearsBoth14N/AUnited States
42NCT00762918
(ClinicalTrials.gov)
March 200826/9/2008Vitamin D3 for the Treatment of Low Vitamin D in Cystic FibrosisVitamin D and Its Non-Classic Roles in Cystic FibrosisCystic Fibrosis;Vitamin D DeficiencyDietary Supplement: cholecalciferolChildren's Hospital of PhiladelphiaNULLWithdrawn10 Years25 YearsBoth0Phase 3United States
43NCT01070446
(ClinicalTrials.gov)
October 200710/2/2010Choline Nutrition in Children With Cystic FibrosisCholine Nutrition in Children With Cystic FibrosisCystic FibrosisDietary Supplement: Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1University of British ColumbiaCystic Fibrosis Foundation (US)Completed5 Years17 YearsBoth34N/ACanada
44NCT01018303
(ClinicalTrials.gov)
August 200719/11/2009Safety and Efficacy of an Antioxidant-rich Multivitamin Supplement in Cystic FibrosisSafety and Efficacy of a Novel Antioxidant-rich Multivitamin Supplement for Persons With Cystic FibrosisCystic FibrosisDietary Supplement: AquADEKUniversity of Colorado, DenverCystic Fibrosis Foundation Therapeutics;Yasoo Health;National Institutes of Health (NIH)Completed10 Years40 YearsBoth17Phase 1/Phase 2United States
45NCT00406536
(ClinicalTrials.gov)
January 200729/11/2006Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PIPhase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CFCystic Fibrosis;Pancreatic InsufficiencyDietary Supplement: Lym-X-Sorb powder;Dietary Supplement: Placebo powderAvanti Polar Lipids, Inc.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed6 Years17 YearsBoth110Phase 2United States
46NCT00730509
(ClinicalTrials.gov)
April 20044/8/2008Effects of 5-Methyltetrahydrofolate and Vitamin B12 Supplemetation on Red Cell Membrane in Children With Cystic FibrosisPreliminary Evidences of Active Form of Folic Acid and Vitamin B12 Supplementation to Ameliorate Cell Membrane in Children With Cystic FibrosisCystic FibrosisDietary Supplement: 5-methyltetrahydrofolate and vitamin B12Universita di VeronaNULLCompleted3 Years8 YearsBoth31N/AItaly
47NCT00530244
(ClinicalTrials.gov)
March 200313/9/2007Use of Formula Fortified With DHA in Infants With Cystic FibrosisThe Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)Cystic FibrosisDietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)University of Massachusetts, WorcesterCystic Fibrosis FoundationCompletedN/A56 DaysAll76N/AUnited States